Viatar CTC Solutions Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2016

Viatar CTC Solutions Inc., formerly Vizio Medical Devices LLC, is a medical technology company. The Company is focused on developing and marketing products to collect cancer cells for molecular diagnostics by others and as cancer therapy, both of which are based on the principle of removing blood-borne circulating tumor cells (CTCs). These CTCs detach from solid tumors and enter the bloodstream carrying the deoxyribonucleic acid (DNA) of the tumor and seeding new tumors. The Company is seeking to commercialize over two products, which utilizes its CTC removal technology, including Viatar Collection System for Molecular Analysis, which collects and purifies a quantity of CTCs from approximately 50 milliliters of blood as the front end for DNA sequencing and other genetic analysis technologies used primarily for research, and Viatar Therapeutic Oncopheresis System, which removes CTCs from a patient's blood as a cancer therapy for metastatic disease.